Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Merck KGaA Rules Out Major M&A, Says MS Pill Mavenclad Will Be Major Earner
Sep 28 2017
•
By
Kevin Grogan
Merck KgAA has been putting its case to the investment community • Source: Shutterstock
More from Deals
More from Business